Pharmacy
Roche to acquire Viewics, Inc.
The FINANCIAL -- Roche on November 17 announced an agreement with Viewics, Inc., a privately held software company focused on...
Pfizer Receives FDA Approval for SUTENT
The FINANCIAL -- Pfizer Inc. on November 16 announced that the U.S. Food and Drug Administration has approved a new...
Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
The FINANCIAL -- AstraZeneca on November 15 announced that the US Food and Drug Administration (FDA) has approved a new...
Takeda Receives Positive CHMP Opinion for ADCETRIS
The FINANCIAL -- Takeda Pharmaceutical Company Limited on November 14 announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
Pfizer Names Albert Bourla Chief Operating Officer
The FINANCIAL -- Pfizer Inc. on November 14 announced that Albert Bourla has been named Chief Operating Officer effective January...
Sanofi, Principia agree to develop multiple sclerosis drug candidate
The FINANCIAL -- Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and,...
Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK
The FINANCIAL -- GlaxoSmithKline plc on November 8 announced that Dr Hal Barron has been appointed Chief Scientific Officer and...
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
The FINANCIAL -- Boehringer Ingelheim and MiNA Therapeutics, a pioneer in RNA activation therapeutics, on November 8 announced that they...
Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
The FINANCIAL -- Spark Therapeutics and Pfizer Inc. on November 7 announced they have entered into an amendment to their...
FDA approves Zelboraf for Erdheim-Chester disease with BRAF V600 mutation
The FINANCIAL -- Roche announced on November 7 that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib)...
Switching to Tresiba is highly cost-effective and cost-saving in a real-world setting
The FINANCIAL -- A new analysis of real-world data has shown that switching to Tresiba (insulin degludec) is highly cost-effective...
Takeda Reports First Half FY2017 Results
The FINANCIAL -- Underlying Revenue grew +6.7% with solid performances across all regions (U.S. +16.7%, Japan +0.3%, Europe & Canada...
Gilead revenue falls 13%
The FINANCIAL -- Gilead Sciences, Inc. announced on October 26 its results of operations for the third quarter ended September...
Amgen reports Q3 non-GAAP earnings per share of $3.27
The FINANCIAL -- Amgen on October 25 announced financial results for the third quarter of 2017. Key results include:
Bristol-Myers Squibb Co. Reports 8% Decline In Q3 Bottom Line
The FINANCIAL -- Bristol-Myers Squibb Company on October 26 reported results for the third quarter of 2017, which were highlighted...
ADVERTISEMENT
Popular Last 24h
-
Justice Department Files Voting Rights Suit Against City of Hazleton, Pennsylvania
-
Crews battle fire at Cleveland Metroparks Zoo’s Rainforest exhibit
-
Ampersand wins £22m five-year contract at London Zoo
-
Boston Calling 2025 lineup: Dave Matthews Band, Luke Combs, and Fall Out Boy to headline
-
Meta Will Test Showing EBay Listings On Facebook Marketplace. EBay Stock Jumps.
-
The UK Government has announced a full asset freeze against Blood and Honour.
-
Fruit Juice Manufacturing Company and its Former President Plead Guilty to Food Safety Crimes
LATEST POSTS
LATESTINTERVIEWS
ADVERTISEMENT
